SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* BDC CAPITAL INC. (Last) (First) (Middle) 5 PLACE VILLE MARIE, SUITE 300 (Street) MONTREAL, QUEBEC, CANADA H3B 5E7 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/01/2011	3. Issuer Name and Ticker or Trading Symbol TRANZYME INC [ TZYM ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Convertible Preferred Stock	(1)	(1)	Common Stock	307,287	(1)	D(4)
Common Exchangeable Shares of Tranzyme Pharma Inc.	(2)	(2)	Common Stock	16,108	(2)	D(4)
Preferred Exchangeable Shares of Tranzyme Pharma Inc.	(3)	(3)	Common Exchangeable Shares of Tranzyme Pharma Inc.(2)	915,430	(3)	D(4)

Explanation of Responses:

1. The shares of Series A Convertible Preferred Stock owned of record by the Reporting Person will convert automatically into the number of shares of Common Stock set forth above, without the payment of any additional consideration upon the closing of the Issuer's initial public offering, which is anticipated to occur on April 6, 2011. The Series A Convertible Preferred Stock does not have an expiration date.

2. These shares of Tranzyme Pharma Inc. will be exchanged for shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering, which is anticipated to occur on April 6, 2011, in a corporate reorganization. These shares are immediately exercisable and have no expiration date.

3. These shares of Tranzyme Pharma Inc. will be converted into Common Exchangeable Shares of Tranzyme Pharma Inc. immediately prior to the closing of the Issuer's initial public offering, which is anticipated to occur on April 6, 2011, in a corporate reorganization. These shares are immediately exercisable and have no expiration date.

4. These securities are owned of record by BDC Capital Inc. BDC Capital Inc. is a wholly owned subsidiary of the Business Development Bank of Canada ("BDC"), a Crown Corporation. Voting and investment decisions are made through a sub committee of the board of directors of the BDC, the Credit/Investment and Risk Committee. The members of that committee are all directors of BDC: Thomas Spencer, Eric Boyko, Stan Bracken-Horrocks, Jean-Rene Halde, Prashant Shanker Pathak and Rosemary Zigrossi, each of whom disclaims beneficial ownership of such securities except to the extent of his on her pecuniary interest therein.

	/s/ Karl Reckziegel, Director, Venture Capital, and /s/ Jean-Francois Pariseau, Director, Venture Capital, for BDC Capital Inc.	04/01/2011
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.